A randomized, double-blind, placebo-controlled phase 2b study tested the inhaled psychedelic GH001 (mebufotenine) in 81 patients with treatment-resistant depression (40 in the GH001 group, 41 in the placebo group).[2][3][7] Štúdia splnila primárny aj sekundárny cieľ, pričom pacienti dostali jednorazové individuálne dávkovanie v jeden deň.[1][2][5] At day 8, the GH001 group had a 15.2 point decrease from baseline in MADRS scores (p<0.0001), while the placebo group had an increase of 0.3 points (difference -15.5 points).[2][3][7] Remisná miera v skupine GH001 bola 57,7 %, v placebovej skupine 0 % (p<0,0001).[2][7] Treatment was well tolerated, with stable vital signs, no sedation, dissociative symptoms, or serious adverse events.[2][7] Štúdia hodnotila zmeny príznakov depresie pomocou škály Montgomery-Åsberg Depression Rating Scale (MADRS).[1][2][3]